Announcement • Aug 22
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHSE:600276) announces an Equity Buyback for CNY 2,000 million worth of its shares. Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces a share repurchase program. Under the program, the company will repurchase up to CNY 2,000 million worth of its shares. The shares will be purchased at a price not exceeding CNY 81.78 per share. The repurchased shares will be used for employee stock ownership scheme or share incentive. The program will be funded from company's own funds. The program will be valid for 12 months. Reported Earnings • Aug 21
Second quarter 2026 earnings: EPS and revenues miss analyst expectations Second quarter 2026 results: EPS: CN¥0.34 (down from CN¥0.40 in 2Q 2025). Revenue: CN¥7.32b (down 14% from 2Q 2025). Net income: CN¥2.18b (down 15% from 2Q 2025). Profit margin: 30% (in line with 2Q 2025). Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Jul 23
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Receive Nmpa Approval for Camrelizumab and Famitinib Combination as First-Line Treatment for Recurrent or Metastatic Cervical Cancer Jiangsu Hengrui Pharmaceuticals Co. Ltd. and its subsidiary, Suzhou Suncadia Biopharmaceuticals Co. Ltd., received notification from the National Medical Products Administration approving the market launch of the Company's innovative drug, camrelizumab for injection in combination with famitinib malate capsules, as a first-line treatment for patients with recurrent or metastatic cervical cancer. With this approval, the targeted immunotherapy combination regimen has now been formally upgraded from second-line ("2L") to first-line ("1L") therapy for advanced cervical cancer. Camrelizumab for injection in combination with famitinib malate is indicated for the first-line treatment of patients with recurrent or metastatic cervical cancer who have PD-L1-positive expression (combined positive score (CPS) = 1), as assessed by a fully validated test method. Camrelizumab for injection has been approved in China for multiple indications, including advanced hepatocellular carcinoma, non-squamous non-small cell lung cancer, esophageal squamous cell carcinoma, advanced nasopharyngeal carcinoma, and others. Famitinib malate capsules were approved in May 2025 for use in combination with camrelizumab for injection in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and have not received bevacizumab treatment, and this indication was converted from conditional approval to full approval in July 2026. This approval is based on a randomized, open-label, controlled, multi-center phase III clinical study of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer (SHR-1210-III-329). A total of 45 study sites in China participated in the study, enrolling 443 patients. All prespecified primary endpoints were met. As of June 10, 2025, the median follow-up in the PD-L1-positive subgroup was 19.5 months, demonstrating that camrelizumab in combination with famitinib malate significantly improved survival benefit in patients with advanced cervical cancer. In the PD-L1-positive population, the median overall survival (OS) was 35.8 months in the combination group versus 23.6 months in the chemotherapy group, corresponding to a significant 36.6% reduction in the risk of death (HR = 0.634). 
